Published in Psychosomatics on March 24, 2010
Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol Psychiatry (2011) 1.01
Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. J Neural Transm (Vienna) (2010) 0.95
Epigenetic Mechanisms Shape the Biological Response to Trauma and Risk for PTSD: A Critical Review. Nurs Res Pract (2013) 0.86
Risk factors for the development of depression in patients with hepatitis C taking interferon-α. Neuropsychiatr Dis Treat (2011) 0.86
The role of cytokines in the pathophysiology of suicidal behavior. Psychoneuroendocrinology (2015) 0.80
Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. Int J Neuropsychopharmacol (2016) 0.78
Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C. Pharmacopsychiatry (2014) 0.77
Association between serotonin transporter gene polymorphism and recurrent aphthous stomatitis. Dent Res J (Isfahan) (2016) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms? Front Mol Neurosci (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (1996) 16.04
Reliability and validity studies of the WHO--Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res (1994) 11.08
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet (2006) 6.27
Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med (2000) 5.58
Epidemiology of hepatitis C. Hepatology (1997) 4.90
Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol (1982) 4.36
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res (2005) 3.94
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics (2003) 3.10
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry (1998) 3.07
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry (2002) 2.87
Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry (2004) 2.83
Epidemiology of hepatitis C in the West. Semin Liver Dis (1995) 2.77
A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry (2000) 2.50
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry (2000) 2.46
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology (1996) 2.22
The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am (1994) 2.16
Practical population group assignment with selected informative markers: characteristics and properties of Bayesian clustering via STRUCTURE. Genet Epidemiol (2005) 2.09
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry (2000) 1.97
Hepatitis C, interferon alfa, and depression. Hepatology (2000) 1.91
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry (2002) 1.73
Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol (2002) 1.66
Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol (1993) 1.62
Interaction between childhood trauma and serotonin transporter gene variation in suicide. Neuropsychopharmacology (2007) 1.60
Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet (2004) 1.57
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry (2007) 1.53
Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry (1999) 1.53
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology (2000) 1.45
Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology (2007) 1.29
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol (2000) 1.17
Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry (2002) 1.13
Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther (2002) 1.13
Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett (2004) 1.07
Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat (2005) 1.07
Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust (2000) 1.05
Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry (2001) 1.05
Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry (1999) 1.03
Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol (1998) 1.01
Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry (2002) 0.99
Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry (2004) 0.93
Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun (2002) 0.92
Current treatment for chronic hepatitis C. Rev Gastroenterol Disord (2001) 0.87
Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic Biol Med (2000) 0.84
Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol (2006) 0.81
Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology (2002) 0.81
[Interferon alpha. Effect, indications, therapy monitoring and side-effects]. Internist (Berl) (2000) 0.76
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA (2007) 6.81
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA (2005) 4.64
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Using Effect Size-or Why the P Value Is Not Enough. J Grad Med Educ (2012) 4.26
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 3.66
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend (2006) 3.40
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet (2004) 3.10
Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend (2004) 3.09
Diagnostic reliability of the Semi-structured Assessment for Drug Dependence and Alcoholism (SSADDA). Drug Alcohol Depend (2005) 3.09
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Effects of the 2011 duty hour reforms on interns and their patients: a prospective longitudinal cohort study. JAMA Intern Med (2013) 2.52
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
A prospective cohort study investigating factors associated with depression during medical internship. Arch Gen Psychiatry (2010) 2.41
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res (2005) 2.35
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Reliability of DSM-IV diagnostic criteria using the semi-structured assessment for drug dependence and alcoholism (SSADDA). Drug Alcohol Depend (2007) 2.26
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Genomewide linkage scan for cocaine dependence and related traits: significant linkages for a cocaine-related trait and cocaine-induced paranoia. Am J Med Genet B Neuropsychiatr Genet (2005) 2.24
Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry (2014) 2.18
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology (2010) 2.16
Genomewide linkage scan for opioid dependence and related traits. Am J Hum Genet (2006) 2.15
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Practical population group assignment with selected informative markers: characteristics and properties of Bayesian clustering via STRUCTURE. Genet Epidemiol (2005) 2.09
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet (2003) 2.07
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol (2007) 1.98
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch Gen Psychiatry (2009) 1.97
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend (2006) 1.96